Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | BCL9 | O00512 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258399 | 0.88 | MC4R (0.51) | MC4RDPP4 | |
| SCHEMBL31258391 | 0.80 | BCL9 (0.47) | ROCK2ROCK1BCL9CTNNB1 | |
| SCHEMBL31258390 | 0.79 | HTR2C (0.51) | ROCK2ROCK1BCL9CTNNB1KIT | |
| SCHEMBL1792830 | 0.70 | MC4R (0.75) | MC4RDPP4 | |
| SCHEMBL31258400 | 0.70 | ROCK2 (0.60) | ROCK2ROCK1 | |
| SCHEMBL3249722 | 0.69 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL3248267 | 0.69 | ROCK2 (0.66) | ROCK2ROCK1 | |
| SCHEMBL31023451 | 0.68 | EPHX2 (0.62) | ROCK2ROCK1 | |
| SCHEMBL4008398 | 0.68 | AKR1C3 (0.61) | DPP4 | |
| SCHEMBL26302856 | 0.68 | AKR1C3 (0.61) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | Nantong Jutai Biotech Co., Ltd. (CN) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | BCL9, BCL9L, BCL2L11 | ROCK2 727/4885ROCK1 380/4885MC4R 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.